These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 12372883)

  • 1. p21 and p53 Immunostaining and survival following systemic chemotherapy for urothelial cancer.
    Jankevicius F; Goebell P; Kushima M; Schulz WA; Ackermann R; Schmitz-Dräger BJ
    Urol Int; 2002; 69(3):174-80. PubMed ID: 12372883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
    Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
    Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WAF1/p21 protein expression is an independent prognostic indicator in superficial and invasive bladder cancer.
    Korkolopoulou P; Konstantinidou AE; Thomas-Tsagli E; Christodoulou P; Kapralos P; Davaris P
    Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):285-92. PubMed ID: 11127920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma.
    Siu LL; Banerjee D; Khurana RJ; Pan X; Pflueger R; Tannock IF; Moore MJ
    Clin Cancer Res; 1998 Mar; 4(3):559-65. PubMed ID: 9533522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pT1 G3 urothelial bladder carcinomas.
    Wolf HK; Stöber C; Hohenfellner R; Leissner J
    Tumour Biol; 2001; 22(5):328-36. PubMed ID: 11553864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of p53 nuclear overexpression in patients of muscle invasive urinary bladder carcinoma treated with cystectomy.
    Hemal AK; Khaitan A; Dinda AK; Gupta NP; Seth A; Dogra PN; Nabi G
    Urol Int; 2003; 70(1):42-6. PubMed ID: 12566814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy.
    Klatte T; Seitz C; Rink M; Rouprêt M; Xylinas E; Karakiewicz P; Susani M; Shariat SF
    J Urol; 2015 Nov; 194(5):1456-62. PubMed ID: 26162296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor mapping of regional immunostaining for p21, p53, and mdm2 in locally advanced bladder carcinoma.
    Jahnson S; Karlsson MG
    Cancer; 2000 Aug; 89(3):619-29. PubMed ID: 10931462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of p21(waf1/cip1) protein in transitional cell bladder tumours and its prognostic value.
    Lipponen P; Aaltomaa S; Eskelinen M; Ala-Opas M; Kosma VM
    Eur Urol; 1998 Sep; 34(3):237-43. PubMed ID: 9732201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators.
    Korkolopoulou P; Givalos N; Saetta A; Goudopoulou A; Gakiopoulou H; Thymara I; Thomas-Tsagli E; Patsouris E
    Hum Pathol; 2005 Aug; 36(8):899-907. PubMed ID: 16112007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 immunohistochemistry in high-grade urothelial carcinoma of the bladder is prognostically significant.
    Hodgson A; Xu B; Downes MR
    Histopathology; 2017 Aug; 71(2):296-304. PubMed ID: 28342221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.
    Sarkis AS; Dalbagni G; Cordon-Cardo C; Zhang ZF; Sheinfeld J; Fair WR; Herr HW; Reuter VE
    J Natl Cancer Inst; 1993 Jan; 85(1):53-9. PubMed ID: 7677935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expression profile of p14, p53 and p21 in tumour cells is associated with disease-specific survival and the outcome of postoperative chemotherapy treatment in muscle-invasive bladder cancer.
    Aljabery F; Shabo I; Gimm O; Jahnson S; Olsson H
    Urol Oncol; 2018 Dec; 36(12):530.e7-530.e18. PubMed ID: 30539751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.
    Osman I; Scher HI; Zhang ZF; Pellicer I; Hamza R; Eissa S; Khaled H; Cordon-Cardo C
    Clin Cancer Res; 1997 Apr; 3(4):531-6. PubMed ID: 9815716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic implications of aberrations in p16/pRb pathway in urothelial bladder carcinomas: a multivariate analysis including p53 expression and proliferation markers.
    Korkolopoulou P; Christodoulou P; Lazaris A; Thomas-Tsagli E; Kapralos P; Papanikolaou A; Kalliteraki I; Davaris P
    Eur Urol; 2001 Feb; 39(2):167-77. PubMed ID: 11223676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
    Tzai TS; Tsai YS; Chow NH
    Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma.
    Salinas-Sánchez AS; Atienzar-Tobarra M; Lorenzo-Romero JG; Sánchez-Sánchez F; Giménez-Bachs JM; Donate-Moreno MJ; Pastor-Navarro H; Hernández-Millán I; Segura-Martín M; Escribano-Martínez J
    Urol Int; 2007; 79(4):321-7. PubMed ID: 18025850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas.
    Kakehi Y; Ozdemir E; Habuchi T; Yamabe H; Hashimura T; Katsura Y; Yoshida O
    Jpn J Cancer Res; 1998 Feb; 89(2):214-20. PubMed ID: 9548450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
    Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
    J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.